Probable predictive biomarkers for tumor response to mTOR inhibitors, as have already been described in glioblastoma, breast and prostate cancer cells, will be the differential expression of mTOR pathway proteins, PTEN, AKT, and S6.[one] Consequently, this details is based on preclinical assays, based upon in vitro cultured tumor mobile strains, https://brucem418bhl2.wikigop.com/user